Dataset Information

Oral vaccination of mice against rodent malaria with recombinant Lactococcus lactis expressing MSP-1(19).

ABSTRACT: AIM:To construct the recombinant Lactococcus lactis as oral delivery vaccination against malaria. METHODS:The C-terminal 19-ku fragments of MSP1 (MSP-1(19)) of Plasmodium yoelii 265-BY was expressed in L. lactis and the recombinant L. lactis was administered orally to BALB/c and C57BL/6 mice. After seven interval vaccinations within 4 wk, the mice were challenged with P. yoelii 265-BY parasites of erythrocytic stage. The protective efficacy of recombinant L. lactis was evaluated. RESULTS:The peak parasitemias in average for the experiment groups of BALB/c and C57BL/6 mice were 0.8+/-0.4% and 20.8+/-26.5%, respectively, and those of their control groups were 12.0+/-0.8% and 60.8+/-9.6%, respectively. None of the BALB/c mice in both experimental group and control group died during the experiment. However, all the C57BL/6 mice in the control group died within 23 d and all the vaccinated mice survived well. CONCLUSION:The results imply the potential of recombinant L. lactis as oral delivery vaccination against malaria.

SUBMITTER: Zhang ZH

PROVIDER: S-EPMC4717040 | biostudies-literature | 2005 Nov

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Oral vaccination of mice against rodent malaria with recombinant Lactococcus lactis expressing MSP-1(19).

Zhang Zhi-Hong ZH Jiang Pei-Hong PH Li Ning-Jun NJ Shi Mi M Huang Weida W

World journal of gastroenterology 20051101 44

<h4>Aim</h4>To construct the recombinant Lactococcus lactis as oral delivery vaccination against malaria.<h4>Methods</h4>The C-terminal 19-ku fragments of MSP1 (MSP-1(19)) of Plasmodium yoelii 265-BY was expressed in L. lactis and the recombinant L. lactis was administered orally to BALB/c and C57BL/6 mice. After seven interval vaccinations within 4 wk, the mice were challenged with P. yoelii 265-BY parasites of erythrocytic stage. The protective efficacy of recombinant L. lactis was evaluated.< ...[more]

PMID: 16437602

Similar Datasets

Project description:Hepatitis-hydropericardium syndrome (HPS) causes severe economic losses in the global poultry industry. The present study aims to explore oral immunization of recombinant Lactococcus lactis and Enterococcus faecalis expressing Hexon protein of fowl adenovirus 4 (FAdV-4). The bacteria L. lactis NZ9000 and E. faecalis MDXEF-1 were, respectively, modified as host strain to deliver truncated Hexon protein (?Hexon) or ?Hexon protein fusing with dendritic cell (DC) targeting peptide (DC-?Hexon) on the surface of bacteria. The expression of target protein in L. lactis NZ9000 and E. faecalis MDXEF-1 were detected by western blot. To evaluate the immune responses and protective efficacies provided by the live recombinant bacteria, chickens were immunized with the constructed ?Hexon-expressing bacteria three times at 2-week intervals, then experimentally challenged with hypervirulent FAdV-4/GX01. The results showed that oral immunizations with the four ?Hexon-expressing bacteria (NZ9000/?Hexon-CWA, NZ9000/DC-?Hexon-CWA, MDXEF-1/?Hexon-CWA, and MDXEF-1/DC-?Hexon-CWA), especially the two bacteria carrying DC-targeting peptide, stimulated higher levels of ?Hexon-specific sera IgG and secretory IgA (sIgA) in jejunal lavage fluid, higher proliferation of peripheral blood lymphocytes (PBLs) and higher levels of Th1/Th2-type cytokines, along with significantly decreased virus loads in liver and more offered protective efficacies against FAdV infection compared with PBS and empty vector control groups (p < 0.01). For chickens in the group MDXEF-1/DC-?Hexon-CWA, the levels of aspartate transaminase (AST), alanine transaminase (ALT) and lactate dehydrogenase (LDH) in sera, and the virus loads in livers were significantly decreased vs. the other three ?Hexon-expressing bacteria (p < 0.01). The pathological changes in the hearts, livers, spleens and kidneys of chickens in MDXEF-1/DC-?Hexon-CWA group were relatively slight compared to infection control group and other three ?Hexon-expressing bacteria groups. The rate of protection in MDXEF-1/DC-?Hexon-CWA group was 90%. The present work demonstrated that cell surface-displayed target protein and immune enhancers in L. lactis and E. faecalis might be a promising approach to enhance immunity and immune efficacy against pathogen FAdV-4 infection.

Dataset Information

Oral vaccination of mice against rodent malaria with recombinant Lactococcus lactis expressing MSP-1(19).

Publications

Oral vaccination of mice against rodent malaria with recombinant Lactococcus lactis expressing MSP-1(19).

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets